Truist Securities Reiterates Viking Therapeutic (VKTX) at Buy, Continues to View VK2809 as Superior to resmetirom, Stock Remains Top 5 Pick for 2022
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $28.00 price target on Viking Therapeutic (NASDAQ: VKTX), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
